LFF-571

Semisynthetic Natural Product / Thiopeptide AntibioticRx: InvestigationalCompound: Investigational

Also known as: GE2270A semisynthetic derivative, LFF571

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

LFF-571 is a semisynthetic thiopeptide antibiotic derived from GE2270A, developed by Novartis. It demonstrates potent in vitro activity against Clostridioides difficile and other gram-positive pathogens. A Phase II clinical trial evaluated LFF-571 versus vancomycin for moderate Clostridioides difficile infection, showing comparable efficacy but not superior outcomes. Development has not progressed to Phase III as of available data.

Mechanism of Action

Inhibits bacterial protein synthesis by binding to elongation factor Tu (EF-Tu) in complex with GTP, preventing aminoacyl-tRNA delivery to the ribosomal A site, thereby halting translation in susceptible gram-positive bacteria.

Routes of Administration

Oral

Goals & Uses

  • Gram-positive bacterial infection treatmentAntimicrobialLow
  • Reduction of CDI recurrenceAntimicrobial / GastrointestinalLow
  • Treatment of Clostridioides difficile infectionAntimicrobialModerate

Contraindications

  • Hypersensitivity to thiopeptide antibiotics or GE2270A derivativesAllergyHigh

Adverse Effects

  • HeadacheNeurologicUncommonPain in the head or upper neck
  • NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
  • VomitingGastrointestinalCommonForceful expulsion of stomach contents
  • Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
  • Abdominal painGastrointestinalUncommonPain or discomfort in the abdomen

Drug Interactions

  • CYP3A4 substratesLow

Population Constraints

  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionInvestigationalNo marketing authorization granted; limited EU trial data publicly available.
  • United StatesInvestigationalInvestigated under IND for CDI; Phase II completed (NCT01232595); no NDA filed as of available data.

Not approved by any regulatory authority. Evaluated in Phase II clinical trials (NCT01232595) for Clostridioides difficile infection. Novartis has not advanced the compound to Phase III registration trials.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack